产品
编 号：F039069
分子式：C26H31ClN2O8S
分子量：567.05
分子式：C26H31ClN2O8S
分子量：567.05
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
500mg
256
In-stock
1g
416
In-stock
5g
920
In-stock
结构图
CAS No: 111470-99-6
产品详情
生物活性：
Amlodipine besylate (Amlodipine benzenesulfonate), an antianginal agent and an orally active dihydropyridine calcium channel blocker, works by blocking the voltage-dependent L-type calcium channels, thereby inhibiting the initial influx of calcium. Amlodipine besylate can be used for the research of high blood pressure and cancer.
体内研究：
Amlodipine besylate (5 mg/kg/day; s.c. for 2 weeks) significantly decreases systolic blood pressure (SBP) in VSMC ATP2B1 KO mice.Amlodipine besylate (10 mg/kg; i.p. once daily for 20 days) causes a significant retardation of tumor growth and prolongs the survival of A431 tumor-bearing mice.Animal Model:ATP2B1loxP/loxP mice
Dosage:5 mg/kg/day
Administration:Subcutaneously implanted osmotic pump for 2 weeks
Result:Significantly decreased the blood pressure.
体外研究：
Amlodipine besylate (20-40 μM; 48 h) reduces BrdU incorporation to 68.6% and 26.3% at concentrations of 20 and 30 μM in A431 cells, respectively.Amlodipine besylate (30 μM; pretreated for 1 h) significantly attenuates the uridine 5′-triphosphate (UTP)-induced increases of [Ca2+]i in A431 cells.Amlodipine besylate (30 μM) inhibits the store-operated Ca2+influx evoked by Thapsigargin in Fluo-3-loaded cells.
Amlodipine besylate (Amlodipine benzenesulfonate), an antianginal agent and an orally active dihydropyridine calcium channel blocker, works by blocking the voltage-dependent L-type calcium channels, thereby inhibiting the initial influx of calcium. Amlodipine besylate can be used for the research of high blood pressure and cancer.
体内研究：
Amlodipine besylate (5 mg/kg/day; s.c. for 2 weeks) significantly decreases systolic blood pressure (SBP) in VSMC ATP2B1 KO mice.Amlodipine besylate (10 mg/kg; i.p. once daily for 20 days) causes a significant retardation of tumor growth and prolongs the survival of A431 tumor-bearing mice.Animal Model:ATP2B1loxP/loxP mice
Dosage:5 mg/kg/day
Administration:Subcutaneously implanted osmotic pump for 2 weeks
Result:Significantly decreased the blood pressure.
体外研究：
Amlodipine besylate (20-40 μM; 48 h) reduces BrdU incorporation to 68.6% and 26.3% at concentrations of 20 and 30 μM in A431 cells, respectively.Amlodipine besylate (30 μM; pretreated for 1 h) significantly attenuates the uridine 5′-triphosphate (UTP)-induced increases of [Ca2+]i in A431 cells.Amlodipine besylate (30 μM) inhibits the store-operated Ca2+influx evoked by Thapsigargin in Fluo-3-loaded cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备